Literature DB >> 7856100

Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line-tropic human immunodeficiency virus type 1 envelope gp120.

A Koito1, L Stamatatos, C Cheng-Mayer.   

Abstract

Prior studies with recombinant viruses constructed in vitro showed that the V2 domain of envelope gp120, in addition to the required V3 domain, enhances the efficiency of infection of primary macrophages by HIV-1. Present structural studies on the gp120s of these recombinant viruses using three human monoclonal antibodies directed to the V3 loop indicate that the V2 domain affects cell tropism by modulating the conformation of the V3 loop. Additional mutational analyses of the V2 domain of the T-cell line-tropic virus HIV-1SF2 reveal that single amino acid sequence changes, mainly those affecting the location of potential N-linked glycosylation sites and the positive charge of this region, can also alter tropism. These amino acid substitutions in the V2 domain, however, do not appear to alter the conformation of the V3 loop. Thus, the V2 domain of gp120 can influence cell tropism through both an effect on V3 as well as via a V3-independent mechanism.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7856100     DOI: 10.1006/viro.1995.1010

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  36 in total

Review 1.  Current concepts in human immunodeficiency virus infection and AIDS.

Authors:  S A Schwartz; M P Nair
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

2.  The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012.

Authors:  C B Zhu; L Zhu; S Holz-Smith; T J Matthews; C H Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

3.  Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations.

Authors:  C Pastore; R Nedellec; A Ramos; S Pontow; L Ratner; D E Mosier
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

4.  Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.

Authors:  Junji Shibata; Kazuhisa Yoshimura; Akiko Honda; Atsushi Koito; Toshio Murakami; Shuzo Matsushita
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

5.  HIV-1 Transmission, Replication Fitness and Disease Progression.

Authors:  Tasha Biesinger; Jason T Kimata
Journal:  Virology (Auckl)       Date:  2008-07-14

6.  Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding.

Authors:  L Stamatatos; C Cheng-Mayer
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

7.  Length polymorphism within the second variable region of the human immunodeficiency virus type 1 envelope glycoprotein affects accessibility of the receptor binding site.

Authors:  D G Fox; P Balfe; C P Palmer; J C May; C Arnold; J A McKeating
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

8.  Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop.

Authors:  Noah G Hoffman; Francoise Seillier-Moiseiwitsch; JaeHyung Ahn; Jason M Walker; Ronald Swanstrom
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

9.  The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.

Authors:  Cheryl J Saunders; Ruth A McCaffrey; Irina Zharkikh; Zane Kraft; Susan E Malenbaum; Brian Burke; Cecilia Cheng-Mayer; Leonidas Stamatatos
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

10.  Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection.

Authors:  Rong Rong; Frederic Bibollet-Ruche; Joseph Mulenga; Susan Allen; Jerry L Blackwell; Cynthia A Derdeyn
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.